Artelo Biosciences (NASDAQ:ARTL) Upgraded to “Strong-Buy” by EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Artelo Biosciences (NASDAQ:ARTL) to a strong-buy rating in a research note released on Tuesday morning, Zacks.com reports.

Separately, HC Wainwright reiterated a buy rating and set a $5.00 target price on shares of Artelo Biosciences in a research report on Wednesday, August 14th.

Artelo Biosciences Price Performance

NASDAQ ARTL opened at $1.12 on Tuesday. The firm has a market capitalization of $3.61 million, a price-to-earnings ratio of -0.35 and a beta of 1.36. The company’s fifty day moving average is $1.24 and its two-hundred day moving average is $1.34. Artelo Biosciences has a 52-week low of $1.00 and a 52-week high of $1.78.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.10. As a group, sell-side analysts expect that Artelo Biosciences will post -2.41 earnings per share for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.